吉瑞治疗

最新新闻

• 评级变动
  H.C. Wainwright Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2025/8/26
• 评级变动
  LifeSci Capital Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2025/6/19
• 公司公告
  GNI Group: Gyre Therapeutics to Participate in U.S. Healthcare Conferences
  JPX · 2026/9/4
• Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate
  Benzinga · 2026/5/7
• 公司公告
  GNI Group: Notice Regarding the Release of Corporate Presentation Materials by Consolidated Subsidiary Gyre Therapeutics, Inc.
  JPX · 2026/6/3
• 公司公告
  GNI Group: Regarding Gyre Therapeutics' Participation in the U.S. Healthcare Conference
  JPX · 2026/9/4
• 评级变动
  Wedbush Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2025/7/15
• 评级变动
  Jefferies Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2025/10/10
• 评级变动
  H.C. Wainwright Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• Gyre Therapeutics Q4 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $37.195M Beat $36.303M Estimate
  Benzinga · 2026/3/12
• H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)
  TipRanks · 2026/8/7
• H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 公司公告
  GNI Group: Notice Regarding the Release of Corporate Presentation Materials by Consolidated Subsidiary Gyre Therapeutics, Inc.
  JPX · 2026/8/27
• 评级变动
  H.C. Wainwright Initiates a Buy Rating on Gyre Therapeutics (GYRE)
  TipRanks · 2025/8/11
• 评级变动
  TR | OpenAI - 4o Maintains Gyre Therapeutics(GYRE.US) With Hold Rating, Raises Target Price to $8.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/24
• 评级变动
  Noble Financial Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2025/3/12
• 评级变动
  Stifel Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2025/6/25
• 公司公告
  Gyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Epstein David M.
  SEC · 2026/7/1
• Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。